We found that treatment of both L.L-pMU45CR and L.L-pNU45CR reduced IL-6 (Fig. 4A), IL-1β (Fig. 4B), and TNF-α (Fig. 4C) expression, and restored IL-10 production (Fig. 4D) which plays a regulatory role in colitis. Here, IL1B is linked to colitis.